These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 30557039)
1. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity. Zhang H; Sun Z; Liu Z; Song C Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039 [TBL] [Abstract][Full Text] [Related]
2. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity. Sinha N; Chowdhury S; Sarkar RR Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795 [TBL] [Abstract][Full Text] [Related]
3. Current trends in Hedgehog signaling pathway inhibition by small molecules. Ghirga F; Mori M; Infante P Bioorg Med Chem Lett; 2018 Oct; 28(19):3131-3140. PubMed ID: 30177379 [TBL] [Abstract][Full Text] [Related]
4. Structural optimization on a virtual screening hit of smoothened receptor. Song S; Jiang J; Zhao L; Wang Q; Lu W; Zheng C; Zhang J; Ma H; Tian S; Zheng J; Luo L; Li Y; Yang ZJ; Zhang X Eur J Med Chem; 2019 Jun; 172():1-15. PubMed ID: 30939349 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype. Infante P; Alfonsi R; Ingallina C; Quaglio D; Ghirga F; D'Acquarica I; Bernardi F; Di Magno L; Canettieri G; Screpanti I; Gulino A; Botta B; Mori M; Di Marcotullio L Cell Death Dis; 2016 Sep; 7(9):e2376. PubMed ID: 27899820 [TBL] [Abstract][Full Text] [Related]
6. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo. Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258 [TBL] [Abstract][Full Text] [Related]
7. State of the art of Smo antagonists for cancer therapy: advances in the target receptor and new ligand structures. Espinosa-Bustos C; Mella J; Soto-Delgado J; Salas CO Future Med Chem; 2019 Mar; 11(6):617-638. PubMed ID: 30912670 [TBL] [Abstract][Full Text] [Related]
8. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor. Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740 [TBL] [Abstract][Full Text] [Related]
9. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin. Danhof R; Lewis K; Brown M Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802 [TBL] [Abstract][Full Text] [Related]
10. Discovery of Hedgehog Antagonists for Cancer Therapy. Khatra H; Bose C; Sinha S Curr Med Chem; 2017; 24(19):2033-2058. PubMed ID: 28302010 [TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity. Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224 [TBL] [Abstract][Full Text] [Related]
12. Design and biological evaluation of phenyl imidazole analogs as hedgehog signaling pathway inhibitors. Sun C; Zhang Y; Wang H; Yin Z; Wu L; Huang Y; Zhang W; Wang Y; Hu Q Chem Biol Drug Des; 2021 Mar; 97(3):546-552. PubMed ID: 32946174 [TBL] [Abstract][Full Text] [Related]
13. Targeting Super-Enhancer-Driven Transcriptional Dependencies Suppresses Aberrant Hedgehog Pathway Activation and Overcomes Smoothened Inhibitor Resistance. Sui Y; Wang T; Mei Y; Zhu Y; Jiang W; Shen J; Yan S; Lu W; Zhao K; Mo J; Wang C; Tang Y Cancer Res; 2024 Aug; 84(16):2690-2706. PubMed ID: 38775809 [TBL] [Abstract][Full Text] [Related]
14. Hedgehog pathway and smoothened inhibitors in cancer therapies. Chahal KK; Parle M; Abagyan R Anticancer Drugs; 2018 Jun; 29(5):387-401. PubMed ID: 29537987 [TBL] [Abstract][Full Text] [Related]
15. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers. Li QR; Zhao H; Zhang XS; Lang H; Yu K Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201 [TBL] [Abstract][Full Text] [Related]
16. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance. Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250 [TBL] [Abstract][Full Text] [Related]
17. Hedgehog Signaling: From Basic Biology to Cancer Therapy. Wu F; Zhang Y; Sun B; McMahon AP; Wang Y Cell Chem Biol; 2017 Mar; 24(3):252-280. PubMed ID: 28286127 [TBL] [Abstract][Full Text] [Related]
18. ABT-199 inhibits Hedgehog pathway by acting as a competitive inhibitor of oxysterol, rather as a BH3 mimetic. Wang J; Zhang Y; Huang WJ; Yang J; Tang WG; Huang TM; Tan WF Acta Pharmacol Sin; 2021 Jun; 42(6):1005-1013. PubMed ID: 32855528 [TBL] [Abstract][Full Text] [Related]
19. Overcoming the resistance mechanisms of Smoothened inhibitors. Dong X; Wang C; Chen Z; Zhao W Drug Discov Today; 2018 Mar; 23(3):704-710. PubMed ID: 29326074 [TBL] [Abstract][Full Text] [Related]
20. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy. Buetti-Dinh A; Jensen R; Friedman R BMC Cancer; 2018 May; 18(1):569. PubMed ID: 29776351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]